PHP
ATYR

Parkman Healthcare Partners’s aTyr Pharma ATYR Stock Holding History

Parkman Healthcare Partners’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-150,000
Closed -$761K – 102
2025
Q2 		$761K Buy
+150,000
New +$590K 0.09% 85

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Parkman Healthcare Partners's ATYR Position: Q3 2025 in Review

Parkman Healthcare Partners sold out of aTyr Pharma (ATYR) in Q3 2025, closing a stake of 150,000 shares — an estimated $761K sold.

Parkman Healthcare Partners first reported a position in ATYR in Q2 2025 and held it in 1 quarter. The position peaked at $761K in Q2 2025. 103 funds tracked by Wall St. Rank hold ATYR as of Q3 2025.

  • Parkman Healthcare Partners reported no remaining aTyr Pharma position as of Q3 2025 after selling out during the quarter.
  • Parkman Healthcare Partners sold 150,000 aTyr Pharma shares in Q3 2025, an estimated $761K.
  • Parkman Healthcare Partners first reported a position in aTyr Pharma in Q2 2025 and held it in 1 quarter.
  • Parkman Healthcare Partners's aTyr Pharma position peaked at $761K in Q2 2025.
  • 103 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2025.

Based on Parkman Healthcare Partners's 13F filing for Q3 2025, filed 14 Nov 2025.